Minimus Spine receives U.S. patent — 5 things to know

Spinal Tech

Minimus Spine received a United States patent to cover the Triojection syringe cartridge.

"This patent further strengthens our intellectual property, which will be important as others and are drawn into space," said Minimus Spine's President and CEO David Hooper. "The subject matter included in this patent issued in Europe and Australia last year and we are pleased to be granted similar protection in the United States."

 

Here are five quick facts on the patent:

 

1. The syringe cartilage maintains sterility of the syringe while the devices is processed within the Triojection console.

 

2. Triojection produces and measures ozone in a sterile syringe — the only system doing so.

 

3. The system has a CE mark and was used in the first cases last year.

 

4. Triojection is an alternative to surgery for patients with leg pain associated with disc herniation.

 

5. The initial feedback on procedures preformed last year were positive and the company is progressing on the European post-market study that will randomize patients to compare outcomes and costs associated with Triojection and surgical discectomy.

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers